Idexx Laboratories (IDXX) Consolidated Net Income (2009 - 2026)

Idexx Laboratories' Consolidated Net Income history runs 18 years deep, the most recent figure standing at $278.4 million for Q1 2026.

• In Q1 2026, Consolidated Net Income rose 14.74% year-over-year to $278.4 million; the TTM figure through Mar 2026 stood at $1.1 billion (up 22.38% YoY), while the FY2025 annual figure was $1.1 billion, up 19.33% from the prior year.
• Consolidated Net Income for Q1 2026 stood at $278.4 million, up from $248.2 million in the prior quarter.
• The five-year high for Consolidated Net Income was $294.0 million in Q2 2025, with the low at $132.0 million in Q2 2022.
• The 5-year median for Consolidated Net Income is $216.1 million (2024), against an average of $220.6 million.
• The sharpest annual moves came in 2022 and 2023: Consolidated Net Income tumbled 34.86% in 2022, then surged 69.9% in 2023.
• Idexx Laboratories' Consolidated Net Income stood at $172.2 million in 2022, then advanced by 12.96% to $194.5 million in 2023, then grew by 11.12% to $216.1 million in 2024, then advanced by 14.82% to $248.2 million in 2025, then rose by 12.19% to $278.4 million in 2026.
• Business Quant data shows IDXX's Consolidated Net Income at $278.4 million in Q1 2026, $248.2 million in Q4 2025, and $274.6 million in Q3 2025.